On October 27, 2022 Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, reported that it will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial in Q1 2023 (Press release, Monopar Therapeutics, OCT 27, 2022, View Source [SID1234622506]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

November 2022:

Poster of Camsirubicin Phase 1b Clinical Trial Data to be Presented at CTOS 2022

Event: Connective Tissue Oncology Society (CTOS) Annual Meeting Conference
Date: November 16-19, 2022
Location: Vancouver Convention Centre, Vancouver, BC, Canada

December 2022:

Poster of MNPR-202 Preclinical Data to be Presented at ASH (Free ASH Whitepaper) 2022

Event: 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition
Date: December 10-13, 2022
Location: Ernest N. Morial Convention Center, New Orleans, Louisiana

Q1 2023:

Interim go/no-go Analysis for Validive Phase 2b/3 VOICE Clinical Trial

The Company plans to report out the interim go/no-go decision for its Validive Phase 2b/3 VOICE clinical trial in Q1 2023. All patients required for the interim analysis have been enrolled. Patient enrollment will continue, as will adding additional clinical sites (currently 71 sites across the U.S. and Europe), in preparation for a potentially positive interim analysis.